A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-12 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Mechanisms of action == The mechanisms of action of artesunate remains unclear and debatable. Artesunate is a prodrug that is rapidly converted to its active form dihydroartemisinin (DHA). This process involves hydrolysis of the 4-carbon ester group via plasma esterase enzyme. It is hypothesized that the cleavage of endoperoxide bridge in the pharmacophore of DHA generates reactive oxygen species (ROS), which increases oxidative stress and causes malarial protein damage via alkylation. In addition, Artesunate potently inhibits the essential Plasmodium falciparum exported protein 1 (EXP1), a membrane glutathione S-transferase. As a result, the amount of glutathione in the parasite is reduced. In 2016, artemisinin has been shown to bind to a large number targets, suggesting that it acts in a promiscuous manner. There is evidence suggesting DHA inhibition of calcium-dependent ATPase on endoplasmic membrane, which disrupts protein folding of parasites. It has also been reported to target tubulin, favorizing its polymerization.
== Examples == Strategies for improving platinum-based anticancer drugs usually involve changes in the neutral spectator ligands, changes in the nature of the anions (halides vs various carboxylates), or changes in the oxidation state of the metal (Pt(II) vs Pt(IV)). Nanotechnology has been explored to deliver platinum more efficiently in the case of lipoplatin, which is introduced into the tumor sites thereby reducing the chance of toxicity. Cisplatin was the first to be developed. Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%. This application of cisplatin was developed by pediatric oncologist Roger Packer in the early 1980s.
SIRIUS is a Java-based open-source software for the identification of small molecules from fragmentation mass spectrometry data without the use of spectral libraries. It combines the analysis of isotope patterns in MS1 spectra with the analysis of fragmentation patterns in MS2 spectra. SIRIUS is the umbrella application comprising CSI:FingerID, CANOPUS, COSMIC and ZODIAC. SIRIUS, including its web services for structural elucidation, is freely available to use for academic research. Bright Giant GmbH offers subscription-based access to the SIRIUS web services for commercial users. SIRIUS is not suitable for analyzing proteomics MS data.
Sources: en.wikipedia.org
== Tributes == "Referring to the death of Professor Brailsford Robertson yesterday, the Prime Minister (Mr. Scullin) said:— His untimely end has robbed Australia of a brilliant scientist, whose contribution to the Commonwealth's progress would always be remembered. On behalf of the Federal Ministry Mr. Scullin extended his sincere sympathy to Professor Robertson's family, and expressed its appreciation of the great national services which he had rendered." The Argus, 20 January 1930. "Professor Brailsford Robertson was one of Australia's most brilliant scientists. The value of the work he was accomplishing cannot be estimated." Hon. R.L. Butler, Premier of South Australia, 20 January 1930. "The main purpose of [Robertson's] studies was to solve the mystery of physical life in it successive stages of commencement, growth, decline, and cessation, for the benefit of his fellow-men. ... The amount of original work he accomplished in his short life was prodigious. I would be rash to assert that the loss to science, or as I should prefer to say, the loss to humanity, caused by his death is irreparable, but it will probably be a long time before anyone else is able to gather the threads together and produce the fabric he was attempting to weave on his loom." Sir George Murray, Chancellor of the University of Adelaide, 18 March 1932.
Findlay received criticism in July 2026 after her senior staff and MLAs were allegedly directed to no longer use the term "First Nations", but instead to use terms like "Indian". Although "Indian" is generally regarded as an archaic and offensive term, Findlay allegedly argued that its appearance in legal and official documents such as the federal Indian Act justified its use. Findlay denied that such a directive was given. In response to the allegations, former Premier of British Columbia Christy Clark called Findlay "kooky" and said Findlay "cannot win an election." In August 2026, Ian Paton accusing Findlay of offering him a paid job with an MLA's salary if he resigned his seat for her. Similarly, Rosalyn Bird said that when she refused to resign to allow Findlay to run in her riding, she threw a "tantrum," writing "she yelled at me, told me I was being selfish, told me this was about a bigger picture, then she hung up. The conversation was less than a minute." On August 23, 2026 Reann Gasper announced that she would step down as MLA of Abbotsford-Mission and allow party leader Findlay to run for her seat in a by-election. Gasper was promptly hired as Findlay’s deputy chief of staff. Offering an inducement in return for a politician’s resignation is a criminal offence. In August and September 2026, ten Conservative MLAs resigned from the party, criticizing Findlay's leadership.
=== Full division === Archosaurs (crocodilians and birds) and mammals show complete separation of the heart into two pumps for a total of four heart chambers; it is thought that the four-chambered heart of archosaurs evolved independently from that of mammals. In crocodilians, there is a small opening, the foramen of Panizza, at the base of the arterial trunks and there is some degree of mixing between the blood in each side of the heart, during a dive underwater; thus, only in birds and mammals are the two streams of blood—those to the pulmonary and systemic circulations—permanently kept entirely separate by a physical barrier.
Ozata DM, Gainetdinov I, Zoch A, Phillip D, Zamore PD (2019). "PIWI-Interacting RNAs: Small RNAs With Big Functions" (PDF). Nature Reviews Genetics. 20 (2): 89–108. doi:10.1038/s41576-018-0073-3. hdl:20.500.11820/9f12a0e2-1d56-4a44-968d-6f6300efa2b6. PMID 30446728. S2CID 53565676. Secondary source, 2019 Marc S, Weinberg; Kevin V, Morris (August 2016). "Transcriptional Gene Silencing in Humans". Nucleic Acids Research. 44 (14): 6505–6517. doi:10.1093/nar/gkw139. PMC 5001580. PMID 27060137. Secondary source, 2016 Carthew RW, Sontheimer EJ (February 2009). "Origins and Mechanisms of miRNAs and siRNAs". Cell. 136 (4): 642–55. doi:10.1016/j.cell.2009.01.035. PMC 2675692. PMID 19239886. Secondary source, 2009 Hannon GJ, Rossi JJ (September 2004). "Unlocking the Potential of the Human Genome With RNA Interference". Nature. 431 (7006): 371–8. Bibcode:2004Natur.431..371H. doi:10.1038/nature02870. PMID 15372045. S2CID 4410723. Secondary source, 2004
Sources: en.wikipedia.org
The Francis Crick Institute "Francis Harry Compton Crick (1916–2004)" by A. Andrei at the Embryo Project Encyclopedia Francis Crick on Nobelprize.org Portraits of Francis Crick at the National Portrait Gallery, London Crick papers
Marc Laidlaw is an American writer. Between 1997 and 2016, he was a writer for the video game company Valve, where he worked on the Half-Life and Portal series. Before joining Valve, Laidlaw was a novelist working in fantasy and horror. In 1996 he won the International Horror Guild Award for his novel The 37th Mandala. In 2025, Laidlaw's 1983 short story "400 Boys" was adapted as an episode of the Netflix series Love, Death & Robots.
Acute lymphoblastic leukemia (ALL) cells are CD10+. Follicular lymphoma (follicle centre cell lymphoma) are CD10+. Burkitt Lymphoma cells are CD10+. CD10+ diffuse large B cell lymphoma (CD10+ DLBCL) Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor, but CD10+, BCL2+ tumors could have poorer survival. For some authors, CD10 expression in DLBCL does not influence survival. Angioimmunoblastic T cell lymphoma (AITL) are CD10+ and distinguishes AITL from other T cell lymphomas (CD10−) Some benign T cells can be CD10+
=== Colt: The Nebraska Bad Ass === First aired: 1 October 2009 DJ Timmy recruits Mayhem Miller to solve his bully problem... Colt, a tough-talking redneck from Nebraska. Mayhem gives Colt the heavyweight and light heavyweight champion of the King of the Cage, Tony Lopez. Colt tapped out four times in the first round, and got knocked out in the second, so Timmy received $9,000.
Mycoplasma pneumoniae Chlamydia pneumoniae Hepatitis B virus (HBV) Parvovirus B19 Adenovirus (ADV) Respiratory syncytial virus (RSV) The immune cell involvement in polymyalgia rheumatica includes the activation of dendritic cells and monocytes/macrophages, leading to inflammation in the synovium and bursae of the shoulder and hip girdles which is primarily mediated by the innate immune system. There is an altered balance between Th17 and Treg cells, with increased IL-6 levels driving Th17 cell activation. Disturbed B cell distribution and function are also observed, with a decrease in circulating B cells that recover after steroid treatment. Additionally, systemic activation of circulating monocytes is associated with increased IL-6 and IL-1 beta production. Associations of uncertain significance with multiple types of TNF have also been found. Despite the severe pain associated with the condition in multiple muscle groups, as well as the signs of systemic inflammation, muscle biopsies have found no signs of localized inflammation in muscle tissue in patients with PMR. Electromyography studies also typically turn up normal. The only locations known definitively to be inflamed in PMR are the synovial membranes and bursae of joints. Persons having the HLA-DR4 type of human leucocyte antigen appear to have a higher risk of PMR.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.